Introduction: Expression of immune markers is of scientific interest because of their potential roles as predictive biomarkers for immunotherapy. Although the microenvironment of metastatic tumors and/or therapy-inducible histological transformation may affect the expression of these immune markers, there are few data regarding this context.
Introduction
Immune checkpoint inhibitors that target programmed death-ligand 1 (PD-L1) or programmed death-1 (PD-1) receptor have shown dramatic and/or durable responses in a subset of patients with NSCLC. 1 However, our current understanding of the role of immunotherapies in patients *Corresponding author.
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with NSCLC with EGFR mutation after acquisition of resistance to tyrosine kinase inhibitors (TKIs) is so far unclear.
After acquisition of resistance to EGFR TKIs, heterogeneous distribution of resistance mechanisms sometimes occurs between lesions within a patient. 2 Although the difference in resistance mechanisms or a different microenvironment may lead to a heterogeneous expression of immune markers, currently there are no clear data regarding this context. To date, immunotherapies in patients with EGFR-mutant NSCLCs have shown poorer responses, 3, 4 which identifies the need for a better understanding of immune marker expression in EGFRmutant tumors, although smoking status and/or tumor neoantigens (mutational load) may also affect the efficacy of immunotherapies. 1 In this study, we analyzed the expression of immune markers in isogenic lesions obtained at autopsy, comparing lesions with different resistance mechanisms and those with different metastatic sites. Here we have focused on SCLC transformation versus the EGFR T790M mutation, because their reciprocal relationship has been repeatedly reported 5 despite the lower frequency of SCLC transformation (<5%) as a mechanism of resistance to EGFR TKIs. 6 
Materials and Methods

Specimens Used in This Study
Tumor specimens were obtained at autopsy from a patient with EGFR-mutant NSCLC in whom acquired resistance to gefitinib developed; the specimens were obtained in accordance with ethical guidelines and written informed consent from her legal guardians. Resistance mechanisms in each metastatic lesion were analyzed in our previous study, 5 revealing SCLC transformation (without T790M mutation) in most of the lesions, whereas other lesions were determined to be adenocarcinoma (AC) harboring a T790M mutation.
IHC PD-L1 Analysis
All immunohistochemistry (IHC) staining was performed on the Benchmark XT automated stainer (Ventana Medical Systems, Tucson, AZ). PD-L1 (22C3 pharmDx, Dako/Agilent Technologies, Carpinteria, CA), PD-1 (mouse monoclonal antibody, Ventana Medical Systems), and CD8a (mouse monoclonal antibody, Cell Signaling Technology, Danvers, MA) antibodies were used. The scoring of PD-L1 in tumor cells and stromal cells was independently assessed, and PD-L1 was considered expressed only if membranous or membranous and cytoplasmic staining was present.
Comprehensive Analysis for Immune Markers
The HTG EdgeSeq Immuno-Oncology Assay (HTG Molecular Diagnostics, Inc., Tucson, AZ), which can be used with formalin-fixed paraffin-embedded specimens, 7 was performed to compare expression levels of multiple immune markers. Parsed data for the HTG EdgeSeq Immuno-Oncology Assay panel provided raw counts of 549 immune-related genes. The data were normalized by using total counts. We used a negative binomial to model the count distribution in the sequencing data by using Edge R software 8 and obtained differentially expressed genes by Fisher's exact test. We then computed the q value of the false discovery rate for multiple comparisons.
Results
Heterogeneity in PD-L1 Protein Expression
Two metastatic lesions to the liver and two metastatic lesions to lymph nodes (one with SCLC transformation and the other with AC with T790M mutation) were analyzed. Evaluation of PD-L1 expression in tumor cells revealed that both lesions (lymph node and liver metastases) with AC showed 5% positive staining (Table 1 and Fig. 1A ). On the other hand, neither of the lesions with SCLC transformation showed PD-L1 expression in tumor cells (see Table 1 and Fig. 1B ). For the assessment of PD-L1 expression in stromal noncancerous cells, all lesions except for the liver metastasis with SCLC transformation showed 5% to 10% PD-L1 staining (see Table 1 ).
Heterogeneity in Tumor-Infiltrating Immune Cells
Next, we compared the heterogeneity of tumorinfiltrating lymphocytes (TILs). In the liver metastasis with AC, we found a moderate amount of TILs with CD8-positive and PD-1-negative expression (Fig. 1C) . In the liver metastasis with SCLC transformation, a scant number of TILs was found. On the other hand, both of the lymph node metastases, the one with SCLC transformation (Fig. 1D ) and the AC with T790M mutation (Fig. 1E) , showed a moderate amount of TILs with both CD8 and PD-1 positivity. 
Heterogeneity in mRNA Expression of Immune Markers
We used the HTG EdgeSeq Immuno-Oncology panel to compare other immune checkpoints between lesions. Among the molecules expressed on antigen-presenting cells, 9 perhaps as well as on tumor cells, galectin 9
showed up-regulated expression in lesions with SCLC transformation (Fig. 2A) . We also observed that T-cellcostimulatory ligands 9 were expressed in higher amounts in lesions with SCLC transformation (Fig. 2B) .
Next, we analyzed the gene expression signature, comparing lesions with AC and those with SCLC transformation. Using a false discovery rate value of less than 0.05 and a log fold change value of greater than j2j resulted in the identification of nine genes that are highly expressed in AC and 12 genes that are highly expressed in lesions with SCLC transformation (Fig. 2C) . Because some are well related to interferon (IFN), we used the Interferome database website 10 (http://interferome.its. monash.edu.au/interferome/home.jspx) to evaluate these 21 genes. Interestingly, seven of the nine highly expressed genes in AC are those up-regulated by type I IFN stimulation, whereas five of the 12 highly expressed genes in lesions with SCLC transformation are those down-regulated by type I IFN stimulation (Fig. 2C) . For the statistical evaluation for this relationship, we calculated a correlation coefficient of two log fold change values of the 21 gene sets by the Spearman rank method. For the permutation test, we randomly selected 100,000 times of 21 genes from the gene list of the Interferome database website and obtained a p value of 0.01719. These data suggest a decreased type I IFN signaling in lesions with SCLC transformation compared with in those with AC.
Discussion
PD-L1 is not commonly expressed by all tumor cells but is primarily detected at the tumor-stromal interface, 11 leading to intratumor heterogeneity. Regarding the intertumor heterogeneity, recent studies have found that PD-L1 expression status was similar between treatment-naive primary lesions and pulmonary metastases 12 and between primary lesions and brain metastases. 13 In this study we identified similar PD-L1 expression in tumor cells in both lesions with AC; however, the results of testing for PD-L1 were completely negative in tumor cells in both lesions with SCLC transformation. A recent study by Gainor et al. observed homogeneous distribution of PD-L1 expression between lesions, with no evidence of histological transformation in samples from the autopsies of three patients with acquired resistance to EGFR TKIs (they also reported that PD-L1 expression levels changed after EGFR TKI failure in 28% of patients).
14 Although the difference in PD-L1 expression between these two histological types was not dramatic in our patient (5% in the AC part and 0% in the SCLC part), our results suggest the possibility that the histological change induced as an EGFR TKI resistance mechanism may alter the expression status of PD-L1 in tumor cells. In addition, these results may indicate lower efficacy of PD-1/PD-L1-targeting agents in patients with SCLC transformation. We believe that this is reasonable because de novo SCLCs seem to have lower expression status of PD-L1. 15 We also identified higher galectin 9 expression in lesions with SCLC transformation, which is compatible with our recent analysis for de novo SCLC cell lines. 16 Regarding the immune status of the tumor microenvironment, including TILs or PD-L1 expression in noncancerous cells, the aforementioned study 13 reported that the brain metastases often lacked either PD-L1 expression or TILs or both, even when they were present in the primary lung cancer specimens. We also observed differences in these markers in stromal cells between lesions, even when we compared lesions with the same histological type but different metastatic organs. These results indicate the complexity of using these biomarkers for the prediction of response to immunotherapy.
We also observed downregulation of the type I IFNregulated genes in lesions with SCLC transformation (Fig. 2C) . As summarized in a recent review, 17 type I IFNs have a major role not only in antiviral immune responses but also in the natural and therapy-induced immunological control of virus-unrelated malignancies. Because PD-1/PD-L1 signaling potentially plays a minor role in SCLCs, we consider it possible that downregulation of type I IFN signaling plays an important role in SCLCs. Although this study includes only one patient who did not receive immunotherapy, which represents a limitation to generalization of our findings, our data are unique and valuable. This study suggests that the PD-L1 expression status in tumor cells can change after a histological transformation and that immune markers of the tumor microenvironment are complicated.
